INTRODUCTION: Thyroid cancer (TC) is diagnosed in several histological types which differ in their clinical characteristics and survival. We aim to describe how they influence TC survival in Sweden. METHODS: Cancer data were obtained from the Swedish cancer registry between years 1999 and 2018, and these were used to analyze relative survival. RESULTS: Relative survival for all TC improved when analyzed in 10-year periods, and female survival improved more than male survival. Female survival advantage appeared to be present also for specific histological types, although case numbers were low for rare types. Female 5-year relative survival for TC was 100% for follicular, 95.1% for oncocytic, 93.4% for papillary, 89.7% for medullary, and 6.1% for anaplastic cancer. Among the clinical TNM classes, only T4 and M1 stages were associated with decreased survival compared to T1-3 and M0. Anaplastic cancer presented most often at high T and M1 stages, in contrast to other TC. Curiously, the diagnostic age for anaplastic M1 patients was lower than that for M0 patients. Both anaplastic and medullary cancers did not show age-dependent increases in the probability of metastases, in contrast to the main histological types. This could indicate the presence of several types of anaplastic and medullary cancers. CONCLUSION: The poor survival for anaplastic TC is an extreme contrast to the excellent survival of differentiated TC. As less than 20% of anaplastic cancer patients survived one year, urgent diagnosis and initiation of treatment are important. Facilitated treatment pathways have been instituted in Denmark resulting in improved survival. Anaplastic cancer should be a target of a major research focus.

Biomedical Center Faculty of Medicine Charles University Pilsen Czech Republic

Cancer Gene Therapy Group Translational Immunology Research Program University of Helsinki Helsinki Finland

Center for Community Based Healthcare Research and Education Department of Functional Pathology School of Medicine Shimane University Shimane Japan

Center for Primary Health Care Research Lund University Malmö Sweden

Comprehensive Cancer Center Helsinki University Hospital Helsinki Finland

Department of Family Medicine and Community Health Department of Population Health Science and Policy Icahn School of Medicine at Mount Sinai New York NY USA

Department of Otorhinolaryngology Head and Neck Surgery Helsinki University Hospital and University of Helsinki Helsinki Finland

Department of Surgery Charles University Medical School Pilsen Czech Republic

Division of Cancer Epidemiology German Cancer Research Center Heidelberg Germany

Division of Pediatric Neurooncology German Cancer Research Center Heidelberg Germany

Hopp Children's Cancer Center Heidelberg Germany

Skin and Allergy Hospital Helsinki University Hospital and University of Helsinki Helsinki Finland

Zobrazit více v PubMed

Mulita F, Anjum F. Thyroid Adenoma. In: PubMed

La Vecchia C, Malvezzi M, Bosetti C, et al. Thyroid cancer mortality and incidence: a global overview. PubMed DOI

Chen DW, Lang BHH, McLeod DSA, Newbold K, Haymart MR. Thyroid cancer. PubMed

Hemminki K, Eng C, Chen B. Familial risks for nonmedullary thyroid cancer. PubMed DOI

Juhlin C, Mete O, Baloch ZW. The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading. PubMed

Bellini MI, Biffoni M, Patrone R, et al. Poorly differentiated thyroid carcinoma: single centre experience and review of the literature. PubMed DOI PMC

Xu B, Fuchs T, Dogan S, et al. Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases. PubMed DOI PMC

Fallah M, Sundquist K, Hemminki K. Risk of thyroid cancer in relatives of patients with medullary thyroid carcinoma by age at diagnosis. PubMed DOI

Accardo G, Conzo G, Esposito D, et al. Genetics of medullary thyroid cancer: an overview. PubMed DOI

Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. PubMed DOI

Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide thyroid-cancer epidemic? the increasing impact of overdiagnosis. PubMed DOI

Tichanek F, Försti A, Liska V, et al. Early mortality critically impedes improvements in thyroid cancer survival through a half century. PubMed DOI

Dahlberg J, Adok C, Bümming P, et al. Incidence, detection and outcome of differentiated thyroid cancer in Western Sweden. PubMed DOI PMC

Brown KF, Rumgay H, Dunlop C, et al. The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. PubMed DOI PMC

Hu X, Wang X, Liang Y, et al. Cancer risk in Hashimoto’s Thyroiditis: a systematic review and meta-analysis. PubMed DOI PMC

Shu X, J JI, Li X, Sundquist J, Sundquist K, Hemminki K. Cancer risk in patients hospitalised for Graves’ disease: a population-based cohort study in Sweden. PubMed DOI PMC

Hemminki K, Sundquist K, Sundquist J, Försti A, Hemminki A, Li X. Familial risks and proportions describing population landscape of familial cancer. PubMed DOI PMC

Nyström HF, Brantsæter AL, Erlund I, et al. Iodine status in the Nordic countries - past and present. PubMed DOI PMC

Mulita F, Verras GI, Dafnomili VD, et al. Thyroidectomy for the management of differentiated thyroid carcinoma and their outcome on early postoperative complications: a 6-year single-centre retrospective study. PubMed DOI

Mulita F, Plachouri MK, Liolis E, Vailas M, Panagopoulos K, Maroulis I. Patient outcomes following surgical management of thyroid nodules classified as Bethesda category III (AUS/FLUS). PubMed DOI

Mulita F, Iliopoulos F, Tsilivigkos C, et al. Cancer rate of Bethesda category II thyroid nodules. PubMed

Filetti S, Durante C, Hartl D, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. PubMed DOI

Filetti S, Durante C, Hartl DM, et al. ESMO clinical practice guideline update on the use of systemic therapy in advanced thyroid cancer. PubMed DOI

Elia G, Patrizio A, Ragusa F, et al. Molecular features of aggressive thyroid cancer. PubMed DOI PMC

Lin B, Ma H, Ma M, et al. The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis. PubMed PMC

Mirian C, Grønhøj C, Jensen DH, et al. Trends in thyroid cancer: retrospective analysis of incidence and survival in Denmark 1980-2014. PubMed DOI

Janssen-Heijnen ML, Gondos A, Bray F, et al. Clinical relevance of conditional survival of cancer patients in Europe: age-specific analyses of 13 cancers. PubMed DOI

Zitricky F, Försti A, Hemminki A, Hemminki K. Conditional survival in breast cancer up to 10 years in the Nordic countries. PubMed DOI PMC

Zitricky F, Försti A, Hemminki A, Hemminki O, Hemminki K. Conditional survival in prostate cancer in the Nordic countries elucidates the timing of improvements. PubMed DOI PMC

Pukkala E, Engholm G, Hojsgaard Schmidt LK, et al. Nordic cancer registries - an overview of their procedures and data comparability. PubMed DOI

IARC. Cancer Incidence in Five Continents. Vol. IX. Curado M, Edwards B, Shin H, et al., editors. Lyon: IARC; 2007.

Wood SN. Thin-plate regression splines. DOI

Perme MP, Stare J, Estève J. On estimation in relative survival. PubMed DOI

Lambert PC, Dickman PW, Rutherford MJ. Comparison of different approaches to estimating age standardized net survival. PubMed DOI PMC

Nagamine CML, Goulart BNG, Ziegelmann PK. Net survival in survival analyses for patients with cancer: a scoping review. PubMed DOI PMC

Barbieri M, Wilmoth JR, Shkolnikov VM, et al. Data resource profile: the human mortality database (HMD). PubMed DOI PMC

Brenner H, Gefeller O, Hakulinen T. Period analysis for ‘up-to-date’ cancer survival data: theory, empirical evaluation, computational realisation and applications. PubMed DOI

Seppä K, Rue H, Hakulinen T, Läärä E, Sillanpää MJ, Pitkäniemi J. Estimating multilevel regional variation in excess mortality of cancer patients using integrated nested Laplace approximation. PubMed DOI

Nelson CP, Lambert PC, Squire IB, Jones DR. Flexible parametric models for relative survival, with application in coronary heart disease. PubMed

Liu XR, Pawitan Y, Clements M. Parametric and penalized generalized survival models. PubMed DOI

de Ridder M, Nieveen van Dijkum E, Engelsman A, Kapiteijn E, Klümpen HJ, Rasch CRN. Anaplastic thyroid carcinoma: a nationwide cohort study on incidence, treatment and survival in the Netherlands over 3 decades. PubMed DOI

Leandro-García LJ, Landa I. Mechanistic Insights of Thyroid Cancer Progression. PubMed DOI PMC

Zhang L, Ren Z, Su Z, et al. Novel recurrent altered genes in Chinese patients with anaplastic thyroid cancer. PubMed DOI

Kunstman JW, Juhlin CC, Goh G, et al. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. PubMed DOI PMC

Pozdeyev N, Gay LM, Sokol ES, et al. Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. PubMed DOI PMC

Coumans FA, Siesling S, Terstappen LW. Detection of cancer before distant metastasis. PubMed DOI PMC

Raue F, Bruckner T, Frank-Raue K. Similar stage-dependent survival and outcome in sporadic and hereditary medullary thyroid carcinoma. PubMed DOI

Li P, Ding Y, Liu M, Wang W, Li X. Sex disparities in thyroid cancer: a SEER population study. PubMed DOI PMC

Podnos YD, Smith D, Wagman LD, Ellenhorn JD. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. PubMed DOI

Wang LY, Ganly I. Nodal metastases in thyroid cancer: prognostic implications and management. PubMed DOI PMC

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. PubMed DOI

Hvilsom GB, Londero SC, Hahn CH, et al. Anaplastic thyroid carcinoma in Denmark 1996-2012: a national prospective study of 219 patients. PubMed DOI

High familial risks in some rare cancers may pinpoint to hidden germline genetics: focus on esophageal, stomach, small intestinal, testis, thyroid and bone cancers